Marketed
Approval / market date · 2005-06-22
Loading medicine record…
Loading medicine record…
This is a locally preserved regulatory record. Source labeling does not by itself prove efficacy for a condition.
Regulatory product record. The connected regulator reports this product as approved, authorised or currently marketed.
Product data
Linked local records
Substance links use source-reported active ingredients. Condition links come from registered study context and are not efficacy claims.
Regulatory record
Patent and exclusivity fields are preserved from the regulator. They are not a legal opinion and are separate from clinical development.
Approval / market date · 2005-06-22
Clinical development
Phases and statuses are source-reported study stages matched by governed token phrases. They do not prove medicine identity, approval or efficacy.
DRUG · Nabiximols
Glioblastoma · Brain Tumor · Cannabis · Brain Tumor, RecurrentDRUG · Nabiximols
NMO Spectrum Disorder · Spasticity, MuscleDRUG · Nabiximols
Spasticity With Multiple SclerosisDRUG · Nabiximols
Multiple Sclerosis (MS)DRUG · Nabiximols
Spasticity in Participants With Multiple SclerosisSource-reported use
No indication text was reported by the connected sources.
Medicine identity matching
RxNorm normalizes identity; FAERS supplies non-causal post-market signals.
Matched from: DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: CANNABIDIOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: CANNABIDIOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: CANNABIDIOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Safety signals
FAERS/AEMS reports are post-market signals. Counts do not establish causality or incidence and may contain duplicates or reporting bias.
Sources and provenance
02266121 · version 2026-07-24
Retrieved 20/08/2026, 10:36:56Verify at sourceDRUG · GW-1000-02
DRUG · Sativex®
Spasticity · Multiple SclerosisDRUG · Sativex®
Spasticity · Multiple SclerosisDRUG · Sativex
Spasticity · Multiple SclerosisDRUG · Sativex
Multiple SclerosisDRUG · Sativex®
Pain · Peripheral NeuropathyDRUG · Sativex
Pain · Peripheral NeuropathyDRUG · Sativex®
Detrusor Overactivity · Multiple SclerosisDRUG · Sativex®
Palliative Care · Pain · CancerDRUG · Sativex®
Pain · Peripheral NeuropathyDRUG · Sativex
Pain · Diabetic NeuropathyDRUG · Sativex
Pain · CancerDRUG · Nabiximols
Pain · Advanced CancerDRUG · Sativex®
Pain · Peripheral NeuropathyDRUG · Nabiximols
Pain · Advanced CancerDRUG · Nabiximols
Pain · Advanced CancerDRUG · Sativex
Evaluation of Abuse Potential of SativexDRUG · Sativex
Evaluation of Abuse Potential of SativexDRUG · Sativex
Evaluation of Abuse Potential of SativexDRUG · Sativex and ketoconazole
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 · Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4 · Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 InhibitorDRUG · Sativex and omeprazole
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 · Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4 · Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 InhibitorDRUG · Sativex and rifampicin
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 · Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4 · Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 InhibitorDRUG · Sativex and ketoconazole
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 · Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4 · Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 InhibitorDRUG · Sativex and omeprazole
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 · Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4 · Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 InhibitorDRUG · Sativex and rifampicin
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 · Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4 · Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 InhibitorDRUG · Sativex
Food EffectDRUG · Sativex
Food EffectDRUG · Sativex
Food EffectDRUG · Sativex
Food EffectDRUG · Sativex spray and oral moxifloxacin placebo
Effects of Sativex on ECGDRUG · Sativex spray and oral moxifloxacin placebo
Effects of Sativex on ECGDRUG · Sativex
Multiple Sclerosis · SpasticityDRUG · GW-1000-02
Multiple SclerosisDRUG · GW-1000-02
Multiple SclerosisDRUG · GW-1000-02
PainDRUG · GW-1000-02
Pain · Multiple SclerosisDRUG · GW-1000-02
PainDRUG · GW-1000-02
Multiple Sclerosis · SpasticityDRUG · Sativex
Multiple Sclerosis · Neuropathic PainDRUG · Sativex
Hepatic ImpairmentDRUG · Sativex
CancerDRUG · Sativex
CancerDRUG · Sativex®
Multiple Sclerosis · Diabetes · Cancer · Neuropathic PainDRUG · Sativex® and fluconazole concomitantly (Treatment B)
Healthy SubjectsDRUG · Sativex® (Treatment A)
Healthy SubjectsDRUG · Sativex
Malnutrition · Anorexia · Cannabis · Aging · Emergency Service, Hospital · Renal Function · PharmacokineticsDRUG · Nabiximols
Post-Traumatic Stress DisorderDRUG · Sativex
Healthy VolunteersDRUG · Sativex Oromucosal Spray
Attention Deficit Hyperactivity Disorder (ADHD)DRUG · Sativex
RehabilitationDRUG · Sativex
Healthy SubjectsDRUG · Nabiximols
Pain · Advanced CancerDRUG · Sativex
Cannabis DependenceDRUG · Sativex
Healthy VolunteersDRUG · Sativex(Registered Trademark)
Cannabis · Dependence · Cannabis Abuse · Pharmacokinetics · fMRIDRUG · Cannabis Sativa extract Oromucosal spray
Motor Neuron Disease · Amyotrophic Lateral Sclerosis (ALS)DRUG · Sativex
Head and Neck Squamous Cell CarcinomaDRUG · Sativex
Spasticity · Multiple SclerosisDRUG · Sativex
Renal Insufficiency · Kidney DiseaseDRUG · Sativex buccal spray
PainDRUG · Sativex
Advanced CancerDRUG · Sativex
Cannabis DependenceDRUG · Sativex
Neuropathic PainDRUG · Sativex®
Multiple SclerosisDRUG · Sativex
Multiple SclerosisDRUG · Sativex Low Dose
Palliative Care · Pain · CancerDRUG · Sativex Medium Dose
Palliative Care · Pain · CancerDRUG · Sativex High Dose
Palliative Care · Pain · CancerDRUG · Sativex
Multiple SclerosisMatched from: DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: CANNABIDIOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: CANNABIDIOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: CANNABIDIOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: CANNABIDIOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: SATIVEX
Official RxNorm recordMatched from: CANNABIDIOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Official RxNorm recordMatched from: SATIVEX
Official RxNorm recordMatched from: DELTA-9-TETRAHYDROCANNABINOL (CANNABIS SATIVA EXTRACT)
Official RxNorm record